Durability of Vaccine Responses

PHASE4RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Vaccine Response
Interventions
BIOLOGICAL

Live Attenuated Yellow Fever 17D Vaccine

The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.

BIOLOGICAL

Quadrivalent seasonal influenza vaccine

The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.

Trial Locations (3)

30030

RECRUITING

The Hope Clinic of Emory University, Decatur

30322

RECRUITING

Emory University Hospital, Atlanta

RECRUITING

Emory Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

Defense Advanced Research Projects Agency

FED

collaborator

Open Philanthropy

OTHER

lead

Emory University

OTHER